Therapeutics / Biologics

For more information on UTMDACC technologies, please contact the Office of Technology Commercialization (713-745-9604).  Please indicate the technology number (MDA#) in your correspondence.

MDA09-036
Discovery of a Functional Protein Complex of Netrin-4, Laminin y1 Chain, and Integrin a6b1 in Mouse Neural Stem Cells
Please contact the office for more information on this technology.

MDA09-027
Anti Human-OX40 Antibody
Please contact the office for more information on this technology.

MDA09-014
Monoclonal Antibody to the Combined Epitope of PR1 Plus HLA-A*0201
Please contact the office for more information on this technology.

MDA09-007
Preparation and Methodology of Silk Fibroin-derived Therapeutic Nanoparticles
Please contact the office for more information on this technology.

MDA08-147
Peptides That Bind Eukaryotic Translation Initiation Factor 4E
Please contact the office for more information on this technology.

MDA08-142
Tumor Targeting siRNA Nanovectors for Treatment of Primary and Metastatic Cancers
Please contact the office for more information on this technology.

MDA08-120
Tumor Growth Inhibition By Relaxin Receptor Silencing Using In Vivo RNA Interference with Chitosan Nanoparticles
Please contact the office for more information on this technology.

MDA08-118
Tumor Targeting siRNA Nanovectors for Treatment of Cancer
Please contact the office for more information on this technology.

MDA08-116
Modulation of Follicular Helper T Cells, a Novel Subset of T Cells
Please contact the office for more information on this technology.

MDA08-107
Therapeutic Targeting of SRC Using siRNA in Neutral Liposomes
Please contact the office for more information on this technology.

MDA08-096
Using Recombinant Bone Marrow Stromal Antigen-2 to Treat Autoimmune Diseases
Please contact the office for more information on this technology.

MDA08-084
Therapeutic Targeting of Paxillin Using siRNA in Neutral Liposomes
Please contact the office for more information on this technology.

MDA08-078
Therapeutic ATP7B siRNA
Please contact the office for more information on this technology.

MDA08-069
Therapeutic Targeting of the Thrombin Receptor (PAR-1) Using SiRNA in Neutral Liposomes (DOPC)
Please contact the office for more information on this technology.

MDA08-065
Therapeutic Targeting of MMP-9 Using siRNA in Neutral Liposomes
Please contact the office for more information on this technology.

MDA08-056
PR1 Target Antigen in Human Breast Cancer
Please contact the office for more information on this technology.

MDA08-031
In Vivo Delivery of Nucleic Acids with rHDL Nanoparticles
Please contact the office for more information on this technology.

MDA08-029
Therapeutic Targeting of EphB4 Using siRNA in Neutral Liposomes
Please contact the office for more information on this technology.

MDA08-025
Therapeutic PVT-1 siRNA
Please contact the office for more information on this technology.

MDA08-017
Redirecting T-cell specificity for CD19 using a human chimeric antigen receptor"
Please contact the office for more information on this technology.

MDA07-128
Tumor cell expression of the Inhibitor of DNA-binding-2 (ID2) as a Target for Cancer Therapy
WO2009/059201

MDA07-109
From Phage Display to Peptidomimetic Design: An Anti-angiogenic Compound that Targets the VEGF Receptor-1 and Neuropilin-1 Pathways
Please contact the office for more information on this technology.

MDA07-104
Peptides Competing with CD74-Fas Complex Enhance Cancer Cell Apoptosis
WO 2009/014702

MDA07-103
Therapeutic Targeting of IL-6 Using siRNA in Neutral Liposomes
Please contact the office for more information on this technology.

MDA07-091
IL-21 as a Novel Target in Inflammatory Diseases
WO 2008/150885

MDA07-087
Dickkopf-1 (DKK1) as a Universal Tumor Vaccine for Immunotherapy of Cancers.
WO/2008/144659

MDA07-079
Liposomal Small Interference RNA Against STAT3
WO2009/002719

MDA07-071
Tumor Cell Expression of Neuropilin-2 as a Target for Cancer Therapy
Please contact the office for more information on this technology.

MDA07-067
Therapeutic Targeting of Interleukin-8 (IL-8) Using siRNA in Neutral Liposomes (DOPC)
WO/2008/109432

MDA07-061
An Unrecognized Extracellular Function for an Adapter Protein Released from the Cytoplasm into the Tumor Milieu
Please contact the office for more information on this technology.

MDA07-060
RAGE Inhibitor Peptides
WO/2008/154638

MDA07-057
Elimination of Cancer Stem Cells by Immunotherapy Targeting Notch and Numb
WO 2008/108910

MDA07-056
Therapeutic Targeting of Prefoldin 4 (PFDN4) Using siRNA in Neutral Liposomes
WO2008/100922

MDA07-036
Cancer Specific Promoters
US-2009-0192101-A1
WO 2008/070448

MDA07-023
Blocking of LL-37 for the Treatment and Prevention of Psoriasis
WO 2008/076981

MDA07-018
CD44-Targeted Paclitaxel Copolymer Prodrug (HA-TXL)
WO/2008/134528

MDA07-016
TG2 as Target for Treating Pancreatic Ductal Adenocarcinoma
US 2008/0279844
WO 2008/063760

MDA06-117
Combination Therapy Using JAK/STAT Inhibitors and Src Inhibitors in Cancer Therapy
WO2008/077064
WO/2008/077062

MDA06-093
Suppression of Skin Cancer Induction and Skin Cancer Progression by Platelet Activating Factor- and Serotonin Receptor Antagonists
Please contact the office for more information on this technology.

MDA06-066
BTNL2 as a New Immune Regulator
WO 2008/154516

MDA06-065
Orally Bioavailable Caffeic Acid Related Anticancer Drugs
US-2007-0232668-A1

MDA06-035
Anti HERV-K Antibody or Single Chain Fv Antibody Alone or in Combination with Chemotherapy Against HERV-K Positive Human Cancers
US-2008-0019979-A1
WO2007/137279

MDA06-018
Inhibition the Generation of IL-10 Producing OX-40 Receptor
US 2008-0286286 A1
WO2007/084559

MDA06-013
Utility of the Zinc Finger Protein 306 in the Diagnostic and Therapeutics of Colorectal Cancer
US 2007-0298445 A1
WO/2007/103876

MDA05-134
Compositions and Methods for the Direct Therapy of Tumors
US-2007-0196277-A1
WO2007/085026

MDA05-125
Methods to Treat Cancer
US2007-0243191 A1
WO/2008/054431

MDA05-086
A Method of Generating Blood Elements from Non-Hematopoietic Tissue
WO2007/016037

MDA05-084
Compositions and Methods for Stimulation of Lung Innate Immunity
US 2008-0170996 A1
WO2008/085549

MDA05-068
Oncogenic Ras-specific Cytotoxic Compound and Methods of Use Thereof
WO2007/062399

MDA05-035
Ligand-based Cell Surface Profiling of the NCI-60 Cancer Cell Lines with Combinatorial Peptide Libraries
US-2007-0248952-A1
WO/2007/104062

MDA05-003
Liposomal Small Interference RNA (SiRNA)
WO2006/113679
US-2009-0012021-A1

MDA04-113
Compositions and Methods of Use of Targeting Peptides for Diagnosis and Therapy of Human Cancer
US 2006-0239968 A1
WO2004/020999

MDA04-093
Synchronous Selection of Homing Peptides for Multiple Tissues by in Vivo Phage Display
WO2007/046818

MDA04-083
Raman Activated Cell Sorting
WO 2006/060171

MDA04-053
Identification of DeltaDNMT3Bs and Their Role in Regulation of Promoter-Specific Methylation in Tumorigenesis
7,405,287

MDA04-043
A Mutation in KIT Confer Imatinib Resistance in GISTs
7,329,495
Please contact the office for more information on this technology.

MDA04-038
PEA-15 as a Tumor Suppressor Gene
WO/2005/089791

MDA04-030
Targeting Peptides for Diagnosis and Therapy
US-2005-0191294 A1
WO2005/065418
US-2008-0003200-A1

MDA04-017
Breast Cancer Specific Promoter
US-2005-0260643-A1
WO/2005/103251
US 2008-0286860 A1

MDA04-004
Improved Anti-Cancer Effects of the Replication-Competent Oncolytic Adenovirus Delta-24 by a Humanized Form of Yeast Cytosine Deaminase
US-2006-0147420-A1
WO2005/086922
US-2009-0175830

MDA03-037
JAB1 as a Prognostic Marker and a Therapeutic Target for Human Cancer
US2009-0148868

MDA03-021
Chronic Myeloid Leukemia Cells Secrete a Proapoptotic Factor Mediating Cell Death of Normal Bone Marrow Cells but not Leukemic Cells
WO 2006/086638
US2008-0274104

MDA03-013
A New Osteoblast and Chondrocyto-specific Small Secreted Peptide, HA4
US 2006-0253914
WO2004/041205

MDA03-005
Anti-tumor Effect of Mutant Bik Gene
US-2005-0118154-A1
WO2004/089981
US-2009-0075885

MDA03-004
Active Specific Immunotherapy of Brain Metastasis by Lyophilized Insect Cells Producing Interferon-beta
US 2006-0228326 A1
WO2004/037182

MDA02-087
Endostatin and Angiostatin as Targeting Proteins to Deliver Therapeutic or Diagnostic Reagent
US-2004-0005684-A1
WO/2003/093303
US-2007-0134206-A1

MDA02-042
Novel Melanoma Peptide Vaccines Derived from the High Molecular Weight Proteoglycan Antigen
7,348,153

MDA02-029
Endogenous Granzyme B in Non-Immune, Non-Hematopoietic Cells (GrB-NIC), Novel Messenger RNA Encoding the Same, and Uses Thereof
7,074,911
WO2004/028342

MDA01-049
Induction of Tumor Immunity by Controlled Modification of Amino Acid Side Chain Length Using Methyl/Methylene (CH2/CH3)
US 2005-0169934 A1
WO03/076585

MDA01-037
Inhibition of Angiogenesis, Tumor Growth and Metastisis by Fully Human Anti-IL8 (ABX-IL8) in Diverse Types of Tumors
US-2003-0068319-A1
7,067,131
6,924,360
7,090,844
US-2006-0246077-A1
WO/2002/077172
WO/2003/057838
WO/2003/057837
WO/2003/057006

MDA00-056
WWOX - a Putative Tumor Suppressor Gene Mutated in Multiple Cancers
7,060,811

MDA00-049
Identification and Function of a Novel Master Transcription Factor that is Required for Bone Formation
7,160,722
WO02/44380

MDA00-043
Induction of Tumor Immunity by Variants of FBP
7,547,759

MDA00-025
Screening Phage Display Random Peptide Libraries in Humans
US-2004-0048243-A1
US 2004-0170955 A1
7,420,030
US-2005-0074747-A1
7,452,964
WO/2002/020724
WO/2002/020822
WO/2002/020723
WO/2002/020769
WO02/020722
WO 2003/022991
US-2008-0124277-A1
US-2008-0176792
US2009-0104117

MDA00-020
Baculovirus Expressed Interferon Beta Compositions for Inhibiting Primary and Metastatic Cancer
6,872,385
WO01/92484A2

MDA00-017
Discovery of a Novel Candidate Tumor Suppressor Gene CAR-1
6,943,245
7,169,384
WO01/12285

MDA00-004
Fabrication of Biodegradable Microspheres as Carriers for Bioactive Proteins Using a Solid Encapsulation/Single Emulsion/Solvent Extraction Technique
6,962,716
7,291,348

MDA99-042
C-CAM as an Angiogenesis Inhibitor
6,517,828
WO00/73340

MDA97-044
Lipid-Carrier Protein Conjugates - Induction of Autoimmunity for Immunotherapy of Cancer
6,300,308
6,806,354
7,563,446
WO99/33522

MDA97-031
NOE-Y2, A Novel Tumor Suppressor Gene in Ovarian and Breast Carcinomas
7,183,401
WO98/42830

MDA96-053
Cloning of an Osteoblast Specific Transcription Factor
6,518,063
WO98/54322

MDA96-012
Sensitization Of HER-2/neu OverExpressing Cancer Cells To Chemotherapeutic Agents By Adenovirus 5 E1A
6,395,712
7,005,424
WO97/35012

MDA94-022
Cancer Therapies by HER-2 Peptides
6,514,942
US-2003-0027766-A1